June 09, 2021
According to the research report titled, ‘Viscosupplementation Devices Market Insights, Competitive Landscape and Market Forecast-2026’, available with Market Study Report LLC, global viscosupplementation devices market is projected to grow considerably between 2021-2026.
Growing prevalence of lifestyle diseases, surging demand for non-surgical treatments for osteoarthritis and rising geriatric population are key factors spurring global viscosupplementation devices market growth.
Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3557559/
Viscosupplementation is basically the process in which liquid greasing is infused into a joint to decrease torment & osteoarthritis movement and encourage better joint development. It aims to therapeutically restore rheological homeostasis in pathological structures like osteoarthritic joints.
Usually, viscosupplementary devices are utilized to restore the normal rheological condition of solid tissue compartments whose normal viscoelasticity is reduced. In addition to this, rapid developments in hyaluronic acid-based therapies, growing demand for minimally invasive treatments, and increasing focus of businesses towards launching innovative arthritis care drugs will stimulate industry growth.
However, high cost of hyaluronic acid-based treatments and concerns over its limited effectiveness are key factors poised to inhibit industry growth over the study period.
As per procedure type, global viscosupplementation devices market is bifurcated into single-injection procedure, five-injection procedure, and three-injection procedure.
The application scope of this marketplace consists of hip osteoarthritis, knee arthritis, and others. Based on end-user spectrum, the industry vertical is segregated into clinics, hospitals, and ambulatory surgical centers.
Speaking of geographical analysis, the industry is fragmented into U.S., Italy, Germany, France, Spain, United Kingdom, and Japan.
The competitive terrain of global viscosupplementation devices market is defined by Sanofi S.A., Anika Therapeutics Inc, Regen Lab SA, Seikagaku Corporation, Ferring B.V., Smith & Nephew plc, Zimmer Biomet Holdings Inc., Allergan Inc., Fidia Farmaceutici S.P.A, Bioventus, LG Life Sciences Ltd., Lifecore Biomedical LLC, and F. Hoffmann-La Roche AG.